Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Progression Free Survival (PFS) — 12.9; 18.5 Months

Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants

Primary: PET Response Rate in Metastatic Prostate Cancer Patients Treated With Zoledronate Therapy. — .091 Proportion of participants with response

Primary: Overall Survival (Favorable and Unfavorable ) — 13.9; 36.3 months

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy — 13; 7; 6 participants

Primary: The Number of Participants With Improvement, Disease Progression or Stable Disease — 6; 4; 13 Participants

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844

Primary: Time to the First On-Study SRE (Non-inferiority) — 521.0; 629.0 Days — p=0.0002

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants

Primary: Skeletal-related Event-free Survival in Men With Bone Metastases From Prostate Cancer — 58; 49; 201; 214 participants

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Time to First Skeletal Related Event — 31.9; 28.8 months — p=0.385

Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: Biochemical Response Rate — 0 participants

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Patient Bone Scan Response Rate — 22.2; 57.9; 50.0; 0 Percentage — p=0.0109

Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants

Primary: Progression-free Survival — 13 months

Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 — -1; 5.6 Percent Change from Baseline — p=<0.0001

Primary: Symptomatic Skeletal Event Free Survival (SSE-FS) — 22.3; 26.0 Months — p=0.2636

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths — 11; 7; 7; 4 participants

Primary: Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose — 85; 118 Participants